Full-Time

R&D Data Modeling Manager Associate

Confirmed live in the last 24 hours

Deadline 7/31/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Junior, Mid

Hyderabad, Telangana, India

Category
Lab & Research
Life Sciences
Required Skills
NoSQL
Information Architecture
Requirements
  • Experience in Pharm domain, Data Governance, Data flows, business data management, information & data architecture, technology or another related field
  • Demonstrated ability to understand end-to-end data use and business needs
  • Experience in Conceptual and Logical modeling
  • Identify and define data domain hierarchies, expertise to data security and privacy standards, Knowledge of R&D data and data domains (e.g., across research, clinical, regulatory etc)
  • Experience with creating and applying data modelling (conceptual, logical and physical) best practices and naming conventions
  • Strong analytical problem-solving skills
  • Demonstrated strong attention to detail, quality, time management and customer focus
  • Excellent written and oral communications skills
  • Strong networking and negotiating skills to collaborate and influence stakeholders in building and managing R&D level data domain structures using best practices
  • Demonstrated willingness to make decisions and to take responsibility for such
  • Excellent interpersonal skills (team player)
  • Experience with data management practices and technologies (e.g., Collibra, Informatica etc)
  • Familiar with databases (relational, dimensional, NoSQL, etc) and concepts of data integrity
  • Strong knowledge of data architecture (e.g., data lake, data virtualization, hubs etc) and modelling (e.g., 3nf etc) is required
  • Experience with SDLC and pharma R&D platforms; experience with requirements gathering, system design, and validation/quality/compliance requirements
  • Experience managing technology and/or data warehouse projects
  • Familiarity with relationship databases and entity-relationship data modelling
  • Experience with hierarchical data models from conceptualization to database optimization
  • Education: Bachelor’s in computer science, Engineering, Mathematics, Statistics, or related; Masters preferred
Responsibilities
  • Understand the data-related needs for various cross-R&D capabilities (E.g., data catalog, master data management etc) and associated initiatives
  • Design conceptual and logical data models and data dictionaries/ontologies to cater to R&D business needs and functional requirements; lead validation of physical data models
  • Interact with business, R&D Digital, and other data collaborators to translate needs into data solutions
  • Understand data governance policies, standards and procedures for R&D data
  • Maintain modelling and naming standards, and data harmonization, metadata management, and source-to-target data mapping documentation
  • Evaluate and influence projects while serving as “voice-of-business”; map systems/interfaces for data management, set standards for future state, and close gap from current-to-future state
  • Serve as technical and data consultant for R&D initiatives with major platforms/technology implementations
  • Maintain documentation and act as an expert on data definitions, data standards, data flows, legacy data structures / hierarchies, common data models, data harmonization etc. for R&D functions
  • Educate and guide R&D teams on standards and information management principles, methodologies, best practices, etc.

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new medicines and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medications, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and extensive R&D efforts, supported by strategic partnerships and a diverse product pipeline. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Q1 2025 profit grew by 20%, driven by Dupixent and new launches.
  • Tolebrutinib shows promise in treating non-relapsing secondary progressive multiple sclerosis.
  • Sanofi's focus on R&D and strategic acquisitions strengthens its position in immunology.

What critics are saying

  • Increased competition in multiple sclerosis market may impact Sanofi's market share.
  • Potential regulatory delays for tolebrutinib could affect market entry timelines.
  • Integration challenges from recent acquisitions may disrupt Sanofi's operations.

What makes Sanofi unique

  • Sanofi's Sarclisa uses innovative on-body injector for multiple myeloma treatment.
  • Acquisitions of Blueprint Medicines and Vigil Neuroscience expand Sanofi's rare disease portfolio.
  • Dupixent is the first new targeted therapy for chronic spontaneous urticaria in a decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.

Yahoo Finance
Apr 24th, 2025
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%